SCHEMBL22801249

SCHEMBL22801249

CC(C)N(C(C)C)P(OCCc1ccccc1F)N(C(C)C)C(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.45
AOC3 Q16853 1/20 0.42
IDO1 P14902 2/20 0.36
ALOX5 P09917 1/20 0.36
MBTPS1 Q14703 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A3 Q01959 1/20 0.35
MAOB P27338 2/20 0.34
CHRM2 P08172 1/20 0.34
CHRM1 P11229 1/20 0.34
CHRM3 P20309 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPK1 P28482 2/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
LMNA P02545 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
THRB P10828 1/20 0.33
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22801201 0.91 TAAR1 (0.42) TAAR1AOC3IDO1ALOX5MBTPS1
SCHEMBL31289110 0.91 TAAR1 (0.42) TAAR1AOC3IDO1ALOX5MBTPS1
SCHEMBL21178203 0.84 IDO1 (0.46) TAAR1AOC3IDO1SLC6A2SLC6A3
SCHEMBL22801250 0.83 KDM4E (0.34) TAAR1SLC6A2ALDH1A1SMN1; SMN2GAA
SCHEMBL22801234 0.82 IDO1 (0.39) IDO1SLC6A2SLC6A3MAOBALDH1A1
SCHEMBL21178001 0.77 CA1 (0.41) TAAR1AOC3IDO1MEN1KMT2A
SCHEMBL22801232 0.74 TAAR1 (0.42) TAAR1AOC3SLC6A2SLC6A3MAOB
SCHEMBL22801238 0.73 TAAR1 (0.32) TAAR1
SCHEMBL22801251 0.73 TAAR1 (0.47) TAAR1IDO1ALOX5SLC6A2SLC6A3
SCHEMBL21178741 0.72 KDM4E (0.36) TAAR1SLC6A2ALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240425542-A1 CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS NUCORION PHARMACEUTICALS INC (US) 2024-12-26 US disclosed
US-12110311-B2 Cyclic deoxyribonucleotide compounds NUCORION PHARMACEUTICALS, INC. (US) 2024-10-08 US disclosed
US-20220298199-A1 CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS NUCORION PHARMACEUTICALS, INC. 2022-09-22 US disclosed
US-11427550-B2 5-fluorouracil compounds NUCORION PHARMACEUTICALS, INC. (US) 2022-08-30 US disclosed
EP-3999519-A1 CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS NUCORION PHARMACEUTICALS, INC. (US) 2022-05-25 EP disclosed
WO-2021011692-A1 CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS NUCORION PHARMACEUTICALS, INC. (US) 2021-01-21 WO disclosed
US-20200399227-A1 5-FLUOROURACIL COMPOUNDS NUCORION PHARMACEUTICALS, INC. 2020-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220298199-A1 CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS DPYD, TYMP, TYMS TAAR1 4404/4885AOC3 3016/4885IDO1 3984/4885
US-20200399227-A1 5-FLUOROURACIL COMPOUNDS DPYD, DHFR, FAU TAAR1 4315/4885AOC3 2720/4885IDO1 4055/4885
US-20240425542-A1 CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS DPYD, TYMP, TYMS TAAR1 4404/4885AOC3 3016/4885IDO1 3984/4885
US-12110311-B2 Cyclic deoxyribonucleotide compounds DPYD, TYMP, TYMS TAAR1 4404/4885AOC3 3016/4885IDO1 3984/4885
US-11427550-B2 5-fluorouracil compounds DPYD, DHFR, MTHFD1 TAAR1 3838/4885AOC3 1560/4885IDO1 3948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.